# Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

> **NCT02117219** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 67 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** MEDI4736 Evaluate MEDI4736 in MDS
- **DRUG:** VIDAZA
- **BIOLOGICAL:** tremelimumab

## Key facts

- **NCT ID:** NCT02117219
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-20
- **Primary completion:** 2019-04-30
- **Final completion:** 2019-04-30
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2019-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117219, "Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02117219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*